Minimal Clinically Important Difference on Parkinson’s Disease
Sleep Scale 2nd Version
Table 1
The demographic and disease-specific characteristics of the study population () at baseline examination.
Mean or number of patients
Standard deviation
Median
Percentile 25
Percentile 75
Age
64.83
9.20
65.00
59.00
72.00
Sex
285M/128F
Education (years)
11.9
3.4
12.0
11.0
16.0
Disease duration
9.91
5.99
9.00
5.00
13.00
HYS (number of patients at stage 1/2/3/4/5)
68/125/170/35/15
Patients on levodopa (baseline)
215 (52.1%)
Patients on levodopa (follow-up)
265 (64.2%)
Levodopa dosage (baseline, in LED, mg)
585.4
472.1
520.0
200.0
812.5
Levodopa dosage (follow-up, in LED, mg)
735.3
490.4
620.0
350.0
912.5
Patients on dopamine-agonists (baseline)
165 (39.9%)
Patients on dopamine-agonists (follow-up)
324 (78.5%)
Dopamine agonist dosage (baseline, in LED, mg)
215.6
244.9
160.0
.0
320.0
Dopamine agonist dosage (follow-up, in LED, mg)
323.2
234.4
324.0
98.5
420.0
Patients on benzodiazepines (both baseline and follow-up)
44 (10.7%)
Schwab-England
74.2
13.9
80.0
70.0
90.0
MDS-UPDRS nMEDL
14.8
6.5
14.0
10.0
19.0
MDS-UPDRS MEDL
17.0
8.3
16.0
10.0
23.0
MDS-UPDRS ME
40.3
14.8
39.0
29.0
48.0
MDS-UPDRS MC
5.2
3.6
5.0
2.0
7.0
MDS-UPDRS total score
77.2
25.8
74.0
58.0
91.0
PDSS-2 motor symptoms domain
4.7
3.9
5.0
2.0
7.0
PDSS-2 PD symptoms domain
3.6
3.3
4.0
1.0
5.0
PDSS-2 disturbed sleep domain
7.3
4.1
7.0
4.0
10.0
PDSS-2 total score
15.6
9.6
16.0
8.0
21.0
HYS: Hoehn-Yahr Stages; LED: levodopa equivalent dosage; MDS-UPDRS: Movement Disorders Society Sponsored Version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS MC: Motor Complications (Part 4 of MDS-UPDRS); MDS-UPDRS ME: Motor Examination (Part 3 of MDS-UPDRS); MDS-UPDRS MEDL: Motor Experiences of Daily Living (Part 2 of MDS-UPDRS); MDS-UPDRS nMEDL: Non-Motor Experiences of Daily Living (Part 1 of MDS-UPDRS).
